Annovis Bio’s NYSE Compliance Plan Accepted

Annovis Bio ( (ANVS) ) has issued an announcement.

On June 19, 2025, Annovis Bio announced that the New York Stock Exchange (NYSE) accepted its plan to regain compliance with listing standards related to minimum market capitalization and stockholders’ equity. The NYSE has granted Annovis an 18-month period from March 26, 2025, to meet these standards, during which the company’s stock is expected to remain listed, provided it adheres to the plan and other applicable standards. This development does not affect Annovis’s business operations or reporting requirements with the U.S. Securities and Exchange Commission.

The most recent analyst rating on (ANVS) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Annovis Bio stock, see the ANVS Stock Forecast page.

Spark’s Take on ANVS Stock

According to Spark, TipRanks’ AI Analyst, ANVS is a Underperform.

Annovis Bio’s overall stock score reflects significant financial challenges with zero revenue and consistent losses, offset slightly by a debt-free balance sheet. Technical indicators suggest a bearish outlook, and valuation metrics are unattractive. Corporate events create a mixed picture, with regulatory compliance issues countered by progress in drug development. The stock remains speculative, relying heavily on future R&D success.

To see Spark’s full report on ANVS stock, click here.

More about Annovis Bio

Headquartered in Malvern, Pennsylvania, Annovis Bio is a late-stage clinical drug platform company focused on pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease.

Average Trading Volume: 448,323

Technical Sentiment Signal: Sell

Current Market Cap: $52.61M

Learn more about ANVS stock on TipRanks’ Stock Analysis page.